Racial disparities in the surgical management of non-small cell lung cancer
The surgical management of non-small cell lung cancer (NSCLC) in U.S. hospitals varies widely depending on the race of the patient, according to a new study.
Cancer
May 21, 2013 |
not rated yet |
0
Biomarkers discovered that may help predict response to drugs targeting KRAS-mutated NSCLC
Scientists have identified biomarkers that may help predict whether patients with KRAS-mutated non-small cell lung cancer (NSCLC) will respond to concurrent treatment with an MEK inhibitor and a PI3 kinase inhibitor, a drug ...
Cancer
Apr 08, 2013 |
not rated yet |
0
Genetic vulnerability of lung cancer to lay foundation for new drug options
Physician-researchers at UT Southwestern Medical Center have identified a vulnerability of certain lung-cancer cells – a specific genetic weakness that can be exploited for new therapies.
Cancer
Apr 04, 2013 |
not rated yet |
0
|
Greater representation of elderly patients in Phase III trials are needed
The median age of patients diagnosed with advanced non–small-cell lung cancer (NSCLC) has steadily increased over the recent years and is presently 70 years. Despite this, the elderly are significantly underrepresented ...
Cancer
Feb 22, 2013 |
not rated yet |
0
Diabetes drug could hold promise for lung cancer patients
Ever since discovering a decade ago that a gene altered in lung cancer regulated an enzyme used in therapies against diabetes, Reuben Shaw has wondered if drugs originally designed to treat metabolic diseases ...
Cancer
Jan 29, 2013 |
not rated yet |
0
|
EGFR mutation not prognostic factor in non-small cell lung cancer
Recent studies have demonstrated that molecular-targeted agents, such as epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), may prolong survival of selected patients based on tumor biomarkers. The presence ...
Cancer
Jan 15, 2013 |
not rated yet |
0
Patients with EGFR exon 20 insertions have poorer prognosis
Exon 20 insertions are the third most common family of epidermal growth factor receptor (EGFR) mutations found in non–small-cell lung cancer (NSCLC). Little is known about cancers harboring these mutations aside from their ...
Cancer
Jan 15, 2013 |
not rated yet |
0
Study shows immunohistochemistry is reliable screening tool for ALK rearrangement
Favorable results have led to crizotinib gaining approval for the treatment of advanced stage ALK-positive non-small cell lung cancer (NSCLC) in Japan, the United States, Canada, and several other countries in Europe and ...
Cancer
Dec 15, 2012 |
not rated yet |
0
Novel test identifies patients most likely to benefit from ALK inhibition therapy
Approximately one in 20 patients with non-small cell lung carcinoma (NSCLC) has chromosomal aberrations targeting the anaplastic lymphoma kinase (ALK) gene. This has considerable implications for treatment because these patients ...
Medical research
Dec 12, 2012 |
not rated yet |
0
|
Researchers report first success of targeted therapy in most common non-small cell lung cancer
A new study by an international team of investigators led by Dana-Farber Cancer Institute scientists is the first to demonstrate that chemotherapy and a new, targeted therapy work better in combination than chemotherapy alone ...
Cancer
Nov 28, 2012 |
not rated yet |
0
|
Drug resistance biomarker could improve cancer treatment
Cancer therapies often have short-lived benefits due to the emergence of genetic mutations that cause drug resistance. A key gene that determines resistance to a range of cancer drugs has been reported in a study published ...
Cancer
Nov 21, 2012 |
not rated yet |
0
|
Study shows different approach after progression in non-small cell lung cancer patients
Right now, the best known treatment for patients with metastatic non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase gene rearrangements (ALK) or epidermal growth factor receptor mutations (EGFR) is crizotinib ...
Cancer
Nov 15, 2012 |
not rated yet |
0
Statins may help prolong survival in NSCLC resection
Patients who have undergone resection for non-small cell lung cancer (NSCLC) may improve their overall survival and reduce the risk of recurrence by taking statins.
Cancer
Oct 22, 2012 |
not rated yet |
0
Painless skin rash predicts survival benefit from latest lung cancer drug, study finds
(Medical Xpress)—Elderly patients with advanced non small cell lung cancer (NSCLC) who developed a rash within 28 days of receiving the targeted drug erlotinib (Tarceva) survived on average 6.2 months, c ...
Cancer
Oct 17, 2012 |
not rated yet |
0
Study shows fit elderly patients should be considered for therapy
Until there are more validated biomarkers to direct treatment decisions, many physicians use patient age to decide what therapy to give their patients. Literature data report that older patients often go undertreated because ...
Cancer
Oct 15, 2012 |
not rated yet |
0
